Cadent Therapeutics Initiates Phase 1 Study of Lead Compound CAD-1883

CAMBRIDGE, Mass., October 17, 2017 – Precision neuroscience company Cadent Therapeutics has earned a milestone payment from Novartis for the initiation of a Phase1 clinical study of a subtype selective NMDA receptor negative allosteric modulator (NAM) for the treatment of treatment-resistant depression.

Cadent Therapeutics exclusively licensed the intellectual property for compounds that selectively modulate NR2B-containing NMDA receptors to Novartis. Novartis is conducting all research and development for the program.

“We are encouraged that Novartis has advanced our NR2B NAM molecule into clinical studies. This is an important milestone and one that will help support the advancement of Cadent’s pipeline of first-in-class medicines to treat serious neurological diseases,” said Michael Curtis, Ph.D., Chief Executive Officer, Cadent Therapeutics.

Cadent is discovering novel medicines designed to modulate dysregulated activity in the brain, tuning brain rhythms to restore motor and cognitive function. The company is advancing its pipeline of positive allosteric modulators for the treatment of spinocerebellar ataxia (SCA), essential tremor and cognitive impairment in patients with schizophrenia, with plans to enter the clinic in 2018.


Spinocerebellar ataxia (SCA) is a genetic neurodegenerative condition that affects approximately 150,000 people worldwide. Patients are readily identified through genetic testing and most often carry genetic abnormalities called “poly-Q expansions,” similar to those found in patients with Huntington’s disease. Symptoms of spinocerebellar ataxia may include abnormal gait, slurred speech, and poor hand-eye coordination. Currently, there are no approved treatments for spinocerebellar ataxia. The disease is progressive and causes damage to the cerebellum, the region of the brain which regulates motor control and balance.


Essential tremor is a neurological disorder characterized by uncontrollable shaking or tremor in different parts of the body, including the head, arms, hands, neck and chin. It is the most common movement disorder affecting 10 million people in the US alone, and there have been limited improvements in standard of care in more than 40 years. Essential tremor is most prevalent in elderly individuals and often interferes with routine daily activities.


Cadent Therapeutics is a precision neuroscience company developing novel medicines that tune and modulate brain rhythms to restore motor and cognitive function in patients with serious neurological disease. The company leverages its unique precision neuroscience approach combining target specificity, patient selection, drug design and optimization, and novel quantitative endpoints to create first-in-class molecules to treat movement and cognitive disorders. Currently in early clinical development, Cadent Therapeutics is rapidly advancing its pipeline of positive allosteric modulators to treat spinocerebellar ataxia, essential tremor and schizophrenia. The Company also has an exclusive license and collaboration agreement with Novartis to develop a negative allosteric modulator, now in Phase 1 clinical studies for the treatment of treatment resistant depression. Investors include Atlas Venture, Clal Biotechnology Industries, Slater Technology Fund and Novartis. For more information, please visit